id	等位基因	注释文本
107	*6	Patients with opioid dependence and carrying the CYP2D6*6 allele in addition to another no function allele may have an increased response to methadone maintenance therapy (MMT) as compared to patients carrying a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. This drug-variant pair has been assigned a 鈥渘o recommendation鈥?by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect response to MMT.
106	*4	Patients with opioid dependence and carrying the CYP2D6*4 allele in addition to another no function allele may have an increased response to methadone maintenance therapy (MMT) as compared to patients carrying a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. This drug-variant pair has been assigned a 鈥渘o recommendation鈥?by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect response to MMT.
105	*3	Patients with opioid dependence and carrying the CYP2D6*3 allele in addition to another no function allele may have an increased response to methadone maintenance therapy (MMT) as compared to patients carrying a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. This drug-variant pair has been assigned a 鈥渘o recommendation鈥?by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect response to MMT.
104	*2xN	Patients with opioid dependence and carrying the CYP2D6*2xN allele in combination with a normal function allele may have a decreased response to methadone maintenance therapy (MMT) as compared to patients carrying two normal function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a 鈥渘o recommendation鈥?by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect a patient's response to MMT.
103	*2	Patients with opioid dependence and carrying the CYP2D6*2 allele in addition to an increased function allele may have a decreased response to methadone maintenance therapy (MMT) as compared to patients carrying two normal function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a 鈥渘o recommendation鈥?by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect response to MMT.
102	*1xN	Patients with opioid dependence and carrying the CYP2D6*1xN allele in combination with a normal function allele may have a decreased response to methadone maintenance therapy (MMT) as compared to patients carrying two no function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a 鈥渘o recommendation鈥?by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect a patient's response to MMT.
101	*1	Patients with opioid dependence and carrying the CYP2D6*1 allele in addition to an increased function allele may have a decreased response to methadone maintenance therapy (MMT) as compared to patients carrying two normal function alleles or two no function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a 鈥渘o recommendation鈥?by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect response to MMT.

id	证据的ID	总结
14557	1451161371	CYP2D6 1/2xN + 2/2xN are associated with increased response to methadone in people with Opioid-Related Disorders as compared to CYP2D6 1/1.
14556	1451153754	CYP2D6 1/1xN is associated with decreased response to methadone in people with Heroin Dependence as compared to CYP2D6 3/4 + 4/4 + 4/6 (assigned as poor metabolizer genotype phenotype) .
14555	1451156320	CYP2D6 poor metabolizer genotype is not associated with response to methadone in people with Heroin Dependence as compared to CYP2D6 normal metabolizer genotype.
14554	1451156302	CYP2D6 ultrarapid metabolizer genotype is associated with decreased response to methadone in people with Heroin Dependence as compared to CYP2D6 normal metabolizer and poor metabolizers genotypes.
14553	1450374180	CYP2D6 poor and ultrarapid metabolizers are not associated with response to methadone in people with Opioid-Related Disorders as compared to CYP2D6 normal metabolizers.
14552	1449271217	CYP2D6 poor metabolizers and intermediate metabolizers is not associated with response to buprenorphine or methadone in people with Opioid-Related Disorders as compared to CYP2D6 normal metabolizer and ultra-metabolizer.

id	类型	评论
33	Update	CA score added as part of scoring system release. LOE may have automatically changed based on new score but may be subject to further changes upon curator review.
32	Update	Added *2 allele, rewrote phenotype descriptions
31	Update	Added PMID 21589866 to evidence and updated phenotype descriptions
30	Update	Added PMID 17234366 to evidence, updated phenotype descriptions and moved LOE to 3 as a significant study was added.
29	Create	Created

最新招商产品更多>>